当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.

Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.

Abstract：

PURPOSE:As the number of survivors continues to increase with improvements in breast cancer treatment, greater emphasis has been placed on the aesthetic outcome following breast surgery. Effort is made to minimize scarring on the breast, yet patients who require a port for treatment inevitably have a scar on the upper chest from the port itself. We hypothesized that patients with breast cancer are conscious of their port scars, and if given a choice would prefer placement of the port in the arm rather than the chest. METHODS:Female breast cancer patients treated at our Breast Center who had a port placed from 2009 to 2015 were asked to complete a 20-question, anonymous survey via SurveyMonkey® reporting demographics and treatment information, and a validated Patient Scar Assessment Questionnaire (PSAQ). RESULTS:Of 139 identified, 105 had email information available for contact, and 67 (64%) patients responded. Of the 67, 37 (55%) had undergone arm placement and 30 (45%), chest. Sixty (92%) patients report noticing their scars; 44 (69%) believed that their scar was noticeable to others; and 22 of the 44 (50%) made an effort to hide their scar. Thirty-seven patients were offered options for port site placement, and 24 (65%) chose placement in the arm (p = 0.057). CONCLUSION:Most patients are conscious of their port scars and if offered the choice choose placement in the arm rather than the chest. Upper extremity port placement should be further explored as an alternative approach for patients with breast cancer to improve port scar consciousness.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Voci A,Lee D,Ho E,Crane-Okada R,DiNome M

doi

10.1007/s10549-018-4790-2

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

569-572

issue

3

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-4790-2

journal_volume

170

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.

    abstract：:We attempted to develop a highly sensitive and specific method for the detection of circulating tumor DNA (ctDNA) using a digital PCR (dPCR) assay for PIK3CA mutations (i.e., H1047R, E545K, and E542K) in primary breast cancer patients. The sensitivity of the dPCR assay for the mutant alleles was examined using cell li...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3322-6

    authors： Oshiro C,Kagara N,Naoi Y,Shimoda M,Shimomura A,Maruyama N,Shimazu K,Kim SJ,Noguchi S

    更新日期：2015-04-01 00:00:00

  • Mammographic breast density decreases after bariatric surgery.

    abstract：PURPOSE:Breast density (BD), an important risk factor for breast cancer, can change over time in some women, but the underlying mechanism is unclear. Very little is known about the impact of surgical weight loss on BD. Our hypothesis is that weight loss after bariatric surgery is associated with a significant and favor...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4361-y

    authors： Williams AD,So A,Synnestvedt M,Tewksbury CM,Kontos D,Hsiehm MK,Pantalone L,Conant EF,Schnall M,Dumon K,Williams N,Tchou J

    更新日期：2017-10-01 00:00:00

  • Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.

    abstract：PURPOSE:Glutathione S-transferase mu 3 (GSTM3) is an enzyme involving in the detoxification of electrophilic compounds by conjugation with glutathione. Higher GSTM3 mRNA levels were reported in patients with ERα-positive breast cancer who received only tamoxifen therapy after surgery. Thus, this study aimed to clarify ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4897-5

    authors： Lin JH,Tu SH,Chen LC,Huang CC,Chang HL,Cheng TC,Chang HW,Wu CH,Wu HC,Ho YS

    更新日期：2018-11-01 00:00:00

  • The financial impact and drivers of hospital charges in contralateral prophylactic mastectomy and reconstruction: a Nationwide Inpatient Sample hospital analysis.

    abstract：PURPOSE:Rates of contralateral prophylactic mastectomy (CPM) have increased over the last decade; it is important for surgeons and hospital systems to understand the economic drivers of increased costs in these patients. This study aims to identify factors affecting charges in those undergoing CPM and reconstruction. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4315-4

    authors： Bucknor A,Chattha A,Ultee K,Wu W,Kamali P,Bletsis P,Chen A,Lee BT,Cronin C,Lin SJ

    更新日期：2017-09-01 00:00:00

  • Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.

    abstract：PURPOSE:To evaluate the effect of adjuvant chemotherapy on improving the prognosis of patients with stage I triple-negative breast cancer (TNBC). METHODS:TNBC patients diagnosed in the SEER 18 database from 2010 to 2015 were included. Kaplan-Meier plots and log-rank tests were used to compare the differences in breast...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05776-2

    authors： Du ZL,Wang Y,Wang DY,Zhang L,Bian ZM,Deng Y,Xu CS,Lin DC,Xie L,Jia Y,Gao JD,Zhang BL

    更新日期：2020-09-01 00:00:00

  • Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer.

    abstract：AIMS:Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for select...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006462023110

    authors： Zambelli A,Robustelli della Cuna FS,Ponchio L,Ucci G,Da Prada GA,Robustelli della Cuna G

    更新日期：2000-06-01 00:00:00

  • Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.

    abstract：:In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-010-0843-x

    authors： Ma X,Chen C,Xiong H,Li Y

    更新日期：2010-11-01 00:00:00

  • Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study.

    abstract：:The protective effect of vegetables on the risk of breast cancer recurrence is uncertain. We sought to evaluate the association between breast cancer recurrence and vegetable intake including analyses stratified on tamoxifen use. Experimental evidence of anti-carcinogenic activity of phytochemicals in cruciferous vege...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1014-9

    authors： Thomson CA,Rock CL,Thompson PA,Caan BJ,Cussler E,Flatt SW,Pierce JP

    更新日期：2011-01-01 00:00:00

  • Axillary evaluation and lymphedema in women with ductal carcinoma in situ.

    abstract：:Axillary evaluation in women with ductal carcinoma in situ (DCIS) is increasing; however, this may introduce additional morbidity with unclear benefit. Our objective was to examine the morbidity and mortality associated with axillary evaluation in DCIS. We conducted a retrospective cohort study of 10,504 women aged 65...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3890-0

    authors： Coromilas EJ,Wright JD,Huang Y,Feldman S,Neugut AI,Hillyer GC,Chen L,Hershman DL

    更新日期：2016-07-01 00:00:00

  • Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.

    abstract：PURPOSE:Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4985-6

    authors： Guestini F,Ono K,Miyashita M,Ishida T,Ohuchi N,Nakagawa S,Hirakawa H,Tamaki K,Ohi Y,Rai Y,Sagara Y,Sasano H,McNamara KM

    更新日期：2019-01-01 00:00:00

  • The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

    abstract：BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9803-5

    authors： Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

    更新日期：2008-02-01 00:00:00

  • Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

    abstract：PURPOSE:Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS:We constructed a Markov model to assess the cost-effectiveness of four diffe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3978-6

    authors： Diaby V,Adunlin G,Ali AA,Zeichner SB,de Lima Lopes G,Kohn CG,Montero AJ

    更新日期：2016-11-01 00:00:00

  • Predictive factors of nipple involvement in breast cancer: a systematic review and meta-analysis.

    abstract：:Nipple-sparing mastectomy (NSM) provides a cosmetic and psychological benefit for patients, but concerns on nipple involvement (NI) of tumor continue to persist. Several studies have reported factors for predicting NI, but the results were inconsistent and uncomprehensive, making patient selection difficult. The aim o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-015-3385-4

    authors： Zhang H,Li Y,Moran MS,Haffty BG,Yang Q

    更新日期：2015-06-01 00:00:00

  • Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.

    abstract：:This prospective study assessed the endometrial effects of fulvestrant, a pure estrogen-receptor antagonist, in postmenopausal women with breast cancer. This single-center study enrolled postmenopausal patients who had an intact uterus at baseline with progressive metastatic breast cancer on tamoxifen followed by an o...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-008-0248-2

    authors： Morales L,Neven P,Timmerman D,Wildiers H,Konstantinovic ML,Christiaens MR,Tan PN,Paridaens R

    更新日期：2009-09-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract：:Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-4321-9

    authors： Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期：2005-09-01 00:00:00

  • Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.

    abstract：PURPOSE:To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS:The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4030-6

    authors： Madubata CC,Liu Y,Goodman MS,Yun S,Yu J,Lian M,Colditz GA

    更新日期：2016-12-01 00:00:00

  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3752-9

    authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期：2016-04-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0080-8

    authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期：2009-05-01 00:00:00

  • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.

    abstract：PURPOSE:To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing. METHODS:In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer at three hospitals in south Sweden (BRCAsearch, ClinicalTrials.gov Ident...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s10549-017-4584-y

    authors： Nilsson MP,Törngren T,Henriksson K,Kristoffersson U,Kvist A,Silfverberg B,Borg Å,Loman N

    更新日期：2018-02-01 00:00:00

  • Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia.

    abstract：INTRODUCTION:The use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy. Although not yet reported, improper application procedures could result ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3799-7

    authors： Belum VR,de Barros Silva G,Laloni MT,Ciccolini K,Goldfarb SB,Norton L,Sklarin NT,Lacouture ME

    更新日期：2016-06-01 00:00:00

  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract：:Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666155

    authors： Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期：1994-01-01 00:00:00

  • Effects of tea consumption and the interactions with lipids on breast cancer survival.

    abstract：PURPOSE:The effect of tea consumption on breast cancer survival remained to be explored. Meanwhile, green tea favorably facilitates lipid metabolisms in breast cancer survivors. This study aimed to examine the effect of tea consumption and the interactions with lipids on breast cancer survival. METHODS:A total of 1551...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05253-5

    authors： Zhang JY,Liao YH,Lin Y,Liu Q,Xie XM,Tang LY,Ren ZF

    更新日期：2019-08-01 00:00:00

  • Older women's experience with breast cancer treatment decisions.

    abstract：:The purpose of this study was to better understand older women's experience with breast cancer treatment decisions. We conducted a longitudinal study of non-demented, English-speaking women ≥ 65 years recruited from three Boston-based breast imaging centers. We interviewed women at the time of breast biopsy (before th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2921-y

    authors： Schonberg MA,Birdwell RL,Bychkovsky BL,Hintz L,Fein-Zachary V,Wertheimer MD,Silliman RA

    更新日期：2014-05-01 00:00:00

  • Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.

    abstract：:Estrogen receptor (ER) α is essential for estrogen-dependent growth, and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer. Breast cancer patients show a wide range of ERα expression levels and the levels of expression in individual patients c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1672-2

    authors： Yoshimoto N,Toyama T,Takahashi S,Sugiura H,Endo Y,Iwasa M,Fujii Y,Yamashita H

    更新日期：2011-11-01 00:00:00

  • PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

    abstract：PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05376-9

    authors： Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

    更新日期：2019-11-01 00:00:00

  • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

    abstract：:The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n =...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3115-3

    authors： Nilsson MP,Hartman L,Kristoffersson U,Johannsson OT,Borg A,Henriksson K,Lanke E,Olsson H,Loman N

    更新日期：2014-10-01 00:00:00

  • Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.

    abstract：:The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor wit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666480

    authors： Bolla M,Chedin M,Colonna M,Marron-Charrière J,Rostaing-Puissant B,Pasquier D,Panh MH,Winckel P,Chambaz EM

    更新日期：1994-01-01 00:00:00

  • Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

    abstract：:Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a conc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0715-4

    authors： Burks SR,Macedo LF,Barth ED,Tkaczuk KH,Martin SS,Rosen GM,Halpern HJ,Brodie AM,Kao JP

    更新日期：2010-11-01 00:00:00

  • Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1.

    abstract：:Alcohol consumption is a risk factor for breast cancer in humans. Experimental studies indicate that alcohol exposure promotes malignant progression of mammary tumors. However, the underlying cellular and molecular mechanisms remain unclear. Alcohol induces a pro-inflammatory response by modulating the expression of c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1902-7

    authors： Wang S,Xu M,Li F,Wang X,Bower KA,Frank JA,Lu Y,Chen G,Zhang Z,Ke Z,Shi X,Luo J

    更新日期：2012-06-01 00:00:00

  • The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

    abstract：BACKGROUND:Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources. ME...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9679-4

    authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

    更新日期：2008-06-01 00:00:00